Abstract:

Objective   To observe the changes of blood pressure, coagulation and fibrinolytic function of malignant tumor treated with YH-16 united with 3DCRT, and discuss the possibility of hypertension, hemorrhage and thromboembolism caused by YH-16. Methods   30 patients were randomly divided into two groups. The control group (15 patients) received 3DCRT, and the YH-16 group (15 patients) was treated with YH-16 15mg, iv drip, d1～14 when receiving 3DCRT. Serum PT, APTT, Fib, and  D-dimer were measured with an automatic coagulometer on d 0, 3, 7, 14 when YH16 was used. Blood pressure was measured twice in the morning and evening every other day during the treatment. Results    PT and FIb of the YH-16 group on d7, 14 but not APTT, TT, D-dimer, blood pressure, significantly changed in relation to those of the control group. Conclusion    YH-16 impacts the coagulation function of malignant tumor patients.

Key words: Recombinant human endostatin; Malignant tumors; Radiotherapy; Blood pressure; Blood coagulation; Fibrinolysis